Navigation Links
Driven by Launch of Emerging Therapies, Overall Prostate Cancer Drug Market Will Increase by $2 Billion Through 2018
Date:7/27/2009

Emerging Therapies to Treat Metastatic Hormone-Refractory Prostate Cancer Will Capture More Than One-Third of the Market, According to a New Report from Decision Resources

WALTHAM, Mass., July 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that $2 billion growth in the prostate cancer drug market though 2018 will be driven principally by the launch of emerging therapies in the metastatic hormone-refractory population, most notably Dendreon's Provenge.

The new Pharmacor report entitled Prostate Cancer finds that therapies in the metastatic hormone-refractory population -- for which there is significant unmet need -- will capture more than one-third of the overall prostate cancer drug market in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. According to the report, the high sales of the emerging therapies are due to the expectation that these agents can improve overall survival in the hormone-refractory metastatic setting, an achievement attained only by Sanofi-Aventis's Taxotere and, more recently, by the therapeutic cancer vaccine Provenge. Several agents appeared promising in early-stage development but failed in Phase III clinical trials, highlighting the challenge of this achievement.

Through 2018, the launches of Provenge, Roche/Chugai's Avastin, AstraZeneca's zibotentan, Johnson & Johnson's abiraterone and Algeta's Alpharadin will fuel market growth. Specifically, sales of Avastin will be driven by its use in combination with Taxotere and sales of Alpharadin will be driven by its use in patients who are not suitable for treatment with Taxotere, according to the report.

"We forecast Taxotere's patient share will increase in the metastatic hormone-refractory setting as a result of its use in combination with emerging agents such as Avastin," said Decision Resources Analyst Andrew Merron, Ph.D. "The use of Taxotere to treat patients not previously receiving cytotoxic agents will increase over the next decade as oncologists are expected to take a more prominent role in the treatment of prostate cancer patients."

Webinar

Members of the media are welcome to attend our upcoming webinar entitled Reigniting Hope for Therapeutic Cancer Vaccines: What Impact Will Provenge Have on the Prostate Cancer Drug Market? This webinar will be held on Wednesday, August 19, 2009 at 10 a.m. U.S. Eastern Time. For more information, please contact Christopher Comfort at 781-296-2597 or by email at ccomfort@dresources.com.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                    Decision Resources, Inc.
    Christopher Comfort                   Elizabeth Marshall
    781-296-2597                          781-296-2563
    ccomfort@dresources.com               emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline
2. Disabilities Rising Among Workers; Need for Employer-Driven Disability Awareness, Support Efforts Also Increases
3. Blue Cross And Blue Shield Association Survey Shows Consumer Driven Health Plan Enrollees Are Taking More Control of Their Healthcare
4. UniCare Introduces Consumer-Driven Health Products to Give Consumers a Bigger Role in Health Care Decisions
5. Anthem Blue Cross and Blue Shield in Virginia Introduces New Generation of Consumer Driven Health Products
6. Consumer Driven Healthcare Continues To Make Its Mark on Indianapolis Market
7. World Health Report Rankings Driven by Ideology, Skewed Data
8. New EBRI/Commonwealth Fund Research: Enrollment in Consumer-Driven Plans Remains Low, Survey Shows
9. Successful Community-Driven Efforts Against HIV/AIDS Highlighted in Conference Panel
10. Tongue-Driven Device Aids Handicapped
11. Members of consumer-driven health plans choosing less care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... 24, 2017 , ... Accordant Technology, a trusted IT solutions ... an analytics-first approach, layered with machine learning, that provides real-time visibility into the ... cloud to the edge. Through the new partnership, customers get the real-time situational ...
(Date:5/24/2017)... ... May 24, 2017 , ... Fiberstar, Inc., ... the food and beverage industry offers Citri-Fi®, a natural citrus fiber, to improve ... decision process. As a result, labels need to deliver simple, transparent and clear ...
(Date:5/23/2017)... , ... May 23, 2017 , ... Allegheny Health ... open The Alexis Joy D’Achille Center for Women’s Behavioral Health at West Penn ... in western Pennsylvania for women suffering from pregnancy-related depression. Construction of the Center ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... body for exercise professionals, is pleased to announce the organization’s Certified Strength Coach ... The NCSF Certified Strength Coach (CSC) program validates the competency of qualified candidates ...
(Date:5/23/2017)... York (PRWEB) , ... May 23, 2017 , ... ... LifeLabs, a leading equipment provider in the modern ART laboratory, to provide hands-on ... in Ft. Lauderdale, Florida. , NextGen LifeLabs, a MedTech Group Purchasing vendor ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)...  Bayer announced today that the latest research from ... the 53 rd Annual Meeting of the American ... in Chicago . ... liver and thyroid cancers, as well as lymphomas, and ... trial of copanlisib in patients with relapsed or refractory ...
(Date:5/11/2017)... , May 11, 2017  Thornhill Research ... has been awarded an $8,049,024 USD five-year, firm-fixed-priced, ... through the Canadian Commercial Corporation (CCC) ( ... Anesthesia Systems to administer general anesthesia to patients ... "The US Marine Corps have been ...
(Date:5/10/2017)... May 10, 2017 Radiology has become the ... costs have also spiraled to the number one ranking ... radiology than ever before as the most complete and ... patient with lower back pain an MRI may confirm ... for pain, resulting in entirely different treatment protocols.  In ...
Breaking Medicine Technology: